OptimizeRx (OPRX) Non Operating Interest Expenses (2010 - 2026)

OptimizeRx has disclosed Non Operating Interest Expenses across 13 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses fell 29.69% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $4.7 million (down 21.88% YoY), while the FY2025 annual figure was $5.3 million, down 14.06% from the prior year.
• Non Operating Interest Expenses came in at $1.1 million for Q2 2026 at OptimizeRx, down from $1.2 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $1.6 million in Q2 2025 to a low of $1.0 million in Q4 2023.
• Average Non Operating Interest Expenses over 5 years is $1.4 million, with a median of $1.4 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses sank 31.98% in 2023 and jumped 49.43% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $1.5 million in 2022, then slumped by 31.98% to $1.0 million in 2023, then soared by 49.43% to $1.6 million in 2024, then declined by 20.6% to $1.2 million in 2025, then dropped by 9.19% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $1.1 million in Q2 2026, $1.2 million in Q1 2026, and $1.2 million in Q4 2025.